Company
Incannex Healthcare Inc
NASDAQ:IXHL
Incannex Healthcare Inc is a clinical-stage biopharmaceutical company leading the way in developing combination therapeutics that target underlying biological pathways associated with chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. The company's strategy is to advance novel therapies by leveraging evidence-based innovation with the potential to transform the lives of people suffering from these conditions.
55 stories · page 2 of 3
Incannex Healthcare launches Obstructive Sleep Apnoea study for IHL-42X
Results will form a critical component of a future new drug application (NDA).
Incannex Healthcare poised for FY24 with strong cash balance at end-Q123: Edison Investment Research
The clinical-stage pharmaceutical company’s recent inclusion in Standard and Poor’s ASX 300 Index should further enhance its visibility, the research firm said.
Incannex Healthcare fields positive Phase 1 data for anti-inflammatory drug IHL-675A: Edison Investment Research
Incannex is focused on developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies.
Incannex Healthcare moves to Phase 2 in anti-inflammatory drug clinical trials
The next phase of trials will initially recruit patients with rheumatoid arthritis, followed by those with inflammatory bowel disease and lung inflammation.
Incannex Healthcare welcomes positive pre-IND meeting with US FDA for traumatic brain injury treatment IHL-216A
“Feedback from the FDA in the pre-IND meeting indicated that the agency is highly interested in the development of IHL-216A for treatment of traumatic brain injury,” said chief scientific officer Dr Mark Bleackley.